UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 321

Sortiert nach

A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis

CPT: pharmacometrics and systems pharmacology, 2024-06, Vol.13 (6), p.970-981

2024

Volltextzugriff (PDF)

Mechanism-based inactivation of CYP3A by HIV protease inhibitors

The Journal of pharmacology and experimental therapeutics, 2005-02, Vol.312 (2), p.583

2005

Volltextzugriff (PDF)

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2023-04, Vol.9 (2), p.e12404-n/a

2023

Volltextzugriff (PDF)

PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together

CPT: pharmacometrics and systems pharmacology, 2022-06, Vol.11 (6), p.721-730

2022

Volltextzugriff (PDF)

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38

Journal of clinical pharmacology, 2009-08, Vol.49 (8), p.984-998

2009

Volltextzugriff (PDF)

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy

Journal of clinical pharmacology, 2012-06, Vol.52 (6), p.789-797

2012

Volltextzugriff (PDF)

Integrated Analysis of Pharmacokinetic Data Across Multiple Clinical Pharmacology Studies of Prasugrel, a New Thienopyridine Antiplatelet Agent

Journal of clinical pharmacology, 2011-03, Vol.51 (3), p.321-332

2011

Volltextzugriff (PDF)

Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

Pharmacotherapy, 2008-12, Vol.28 (12), p.1483-1493

2008

Volltextzugriff (PDF)

Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel

Journal of cardiovascular pharmacology, 2007-11, Vol.50 (5), p.555-562

2007

Volltextzugriff (PDF)

Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans

Journal of clinical pharmacology, 2008-01, Vol.48 (1), p.53-59

2008

Volltextzugriff (PDF)

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Clinical pharmacology and therapeutics, 2023-06, Vol.113 (6), p.1258-1267

2023

Volltextzugriff (PDF)

Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model

Journal of pharmacokinetics and pharmacodynamics, 2014-12, Vol.41 (6), p.639-654

2014

Volltextzugriff (PDF)

Methodological Comparison of In Vitro Binding Parameter Estimation: Sequential vs. Simultaneous Non-linear Regression

Pharmaceutical research, 2010-05, Vol.27 (5), p.866-877

2010

Volltextzugriff (PDF)

Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

Platelets (Edinburgh), 2009-01, Vol.20 (5), p.316-327

2009

Volltextzugriff (PDF)

Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis

Journal of clinical pharmacology, 2009-08, Vol.49 (8), p.973-983

2009

Volltextzugriff (PDF)

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease

Journal of pharmacokinetics and pharmacodynamics, 2008-12, Vol.35 (6), p.593-618

2008

Volltextzugriff (PDF)

Simultaneous optimal experimental design for in vitro binding parameter estimation

Journal of pharmacokinetics and pharmacodynamics, 2013-10, Vol.40 (5), p.573-585

2013

Volltextzugriff (PDF)

Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics

Journal of clinical pharmacology, 2002-11, Vol.42 (11), p.1219-1227

2002

Volltextzugriff (PDF)

Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing: An Open-Label, Single-Sequence, Clinical Trial

Drugs & aging, 2009-01, Vol.26 (9), p.781-790

2009

Volltextzugriff (PDF)

Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8053-8053

2015

Volltextzugriff (PDF)

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Alzheimer's & dementia, 2023-06, Vol.19 (S7), p.n/a

2023

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis

Cancer chemotherapy and pharmacology, 2001-06, Vol.47 (6), p.525-531

2001

Volltextzugriff (PDF)

Abstract 4001: Relationship between Exposure to the Prasugrel Active Metabolite with TIMI Major/Minor Bleeding in TRITON-TIMI 38

Circulation (New York, N.Y.), 2008-10, Vol.118 (suppl_18)

2008

Volltextzugriff (PDF)

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

Current Medical Research and Opinion, 2008, Vol.24 (8), p.2251-2257

2008

Volltextzugriff (PDF)

Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice

Nature neuroscience, 2021-02, Vol.24 (2), p.214

2021

Volltextzugriff (PDF)

1 – 25 von 321

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(275)
Mit Volltextzugriff
(278)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis

Mechanism-based inactivation of CYP3A by HIV protease inhibitors

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy

Integrated Analysis of Pharmacokinetic Data Across Multiple Clinical Pharmacology Studies of Prasugrel, a New Thienopyridine Antiplatelet Agent

Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel

Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model

Methodological Comparison of In Vitro Binding Parameter Estimation: Sequential vs. Simultaneous Non-linear Regression

Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease

Simultaneous optimal experimental design for in vitro binding parameter estimation

Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics

Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing: An Open-Label, Single-Sequence, Clinical Trial

Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC)

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis

Abstract 4001: Relationship between Exposure to the Prasugrel Active Metabolite with TIMI Major/Minor Bleeding in TRITON-TIMI 38

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice

Suchergebnisse filtern